Sellas Life Sciences stock rose 6% after Merck's $6.7 billion Terns deal sparked buyout rumors in the blood-cancer space. Retail investors view Sella's AML pipeline as a potential target for Pfizer. The move follows Merck's premium paid for a mid-stage leukemia drug, signaling strong demand for such assets.